EN DE
Watch Utah Medical Products Inc for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Utah Medical Products Inc (UTMD) fair value: what the stock is really worth

As of Nov 6, 2026: fair value (intrinsic value) of Utah Medical Products Inc stock $76.26, price $72.23, upside +5.6%, quality 75 out of 100. Rating: fairly valued. Calculated from audited financials with 24 of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare US

UM Utah Medical Products Inc logo Broad data Nov 6, 2026

Utah Medical Products Inc

UTMD · US
Fairly valued, in an uptrend

The stock costs about what our calculation considers fair.

Quality 75/100
Highly profitable · 30.5% net margin (TTM)
Low debt
Generates free cash flow
0.4% dividend yield · Well covered
Ranks above peers (10/15)
Wide moat 73/100
Broad data
Fair value $76.26 · Fairly valued
Insiders bought $66,750 (6M)
Revenue last quarter 12% below a year ago.
Weak Growth (revenue 5y −1.8 %/yr in USD)
Watch Utah Medical Products Inc for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$113.12 $50.25 Fair Value $76.26 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 6, 2026.

How to read this chart

60‑month range $50.25 – $113.12 · fair‑value band $58.65 – $92.44 · the $72.23 price screens below the $76.26 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 6, 2026.

Follow Utah Medical Products in your weekly email

Every Wednesday you see whether Utah Medical Products is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Utah Medical Products, Inc. offers medical devices for the healthcare industry in the United States, Europe, and internationally.

Show moreShow less

It offers fetal monitoring accessories, vacuum-assisted delivery systems, and other labor and delivery tools; DISPOSA-HOOD infant respiratory hoods; and DELTRAN PLUS blood pressure monitoring systems.

The company provides GESCO, an umbilical vessel catheter, including DIALY-NATE disposable peritoneal dialysis sets; PALA-NATE silicone oral protection devices; URI-CATH urinary drainage systems; NUTRI-CATH\NUTRI-LOK feeding device; PICC-NATE, a percutaneous intraepithelial central venous catheter; MYELO-NATE lumbar sampling kits; HEMO-NATE disposable filters; and catheterization procedure tray of instruments and supplies.

In addition, it offers LETZ system to excise cervical intraepithelial neoplasia and other lower genital tract lesions; loop, ball, and needle electrodes; FILTRESSE evacuators; other specialty electrodes and supplies and gynecologic tools; Femcare trocars, cannulae, laparoscopic instruments, and accessories; and EPITOME and OptiMicro electrosurgical devices.

Further, the company provides Filshie Clip female surgical contraception devices; PATHFINDER PLUS, an endoscopic irrigation device; suprapubic catheterization products; LIBERTY, a urinary incontinence treatment and control system; ENDOCURETTE, a curette for uterine endometrial tissue sampling; TVUS/HSG-Cath to assess abnormal or dysfunctional uterine bleeding and other abnormalities of uterus; and LUMIN, a tool to manipulate the uterus in laparoscopic procedures.

Additionally, it offers DELTRAN, a disposable pressure transducer; BioPharm HP-PRT; and pressure monitoring accessories, components, and other molded parts.

It serves neonatal intensive care units, labor and delivery departments, women's health center in hospitals, outpatient clinics, and physician's offices. The company was incorporated in 1978 and is headquartered in Midvale, Utah.

Stock analysis

Utah Medical Products Inc (UTMD) currently trades at $72.23, while our model-based Fair Value estimate is $76.26, so the stock looks roughly fairly valued today (gap 5.3%).

Show more

Valuation

Bull case: the Multiples group reads highest at a median of $83.10 per share, and 11 of the 24 models we run sit above the $72.23 price.

Bear case: the Dividend Discount group reads lowest at $11.06, and 13 of the 24 models stay below the price. Data coverage for this calculation is high.

Scenario range: $58.65 (bear) to $92.44 (bull), the price of $72.23 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 75/100 (high quality), in the Healthcare sector.

Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.

Utah Medical Products Inc reported revenue of $38.5M in FY2025 versus $49.1M in FY2021, a compound −5.9%/yr. Reported net income was $11.3M in FY2025, compounding −6.5%/yr from FY2021.

Key figures

Market cap $230M Micro · P/E ratio 21.6 · P/S ratio 6.59 · EPS (TTM) $3.34 · Dividend yield 0.4% · Net margin 30.5% · Return on equity 8.8% · Return on assets (EBIT) 13.0% (5-year average).

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 73 out of 100 (medium confidence).

What moves the price

The share trades about 6% below its 52-week high and 37% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −44% fair-value upside, at 6%, UTMD screens cheaper than that median.

Fair Value models

Bear $58.65 Fair Value $76.26 Bull $92.44
Price $72.23 · Upside +5.6%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then ($2.60 per share) are deliberately not added. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
FCF DCF $65.12 $75.69 $94.20 82
Growth DCF $66.21 $76.26 $92.44 80
Owner Earnings $64.91 $75.43 $93.84 78
All 24 models by family
DCF Models
FCF DCF $65.12 $75.69 $94.20 82
Owner Earnings $64.91 $75.43 $93.84 78
5Y Revenue Exit $56.92 $67.30 $82.64 74
5Y EBITDA Exit $66.71 $84.05 $107.44 77
5Y P/E Exit $72.00 $93.10 $118.76 72
10Y Revenue Exit $59.78 $67.91 $76.54 68
10Y EBITDA Exit $65.74 $77.55 $90.29 70
10Y P/E Exit $68.66 $82.76 $96.56 65
Earnings-Based
Graham-Dodd $24.17 $34.13 $39.95 67
EPV $48.23 $51.07 $53.42 74
Dividend Discount
Gordon GGM $9.58 $10.46 $11.64 69
DDM Multi-Stage $9.58 $11.66 $14.12 67
Multiples
P/E Multiple $58.65 $78.20 $97.75 63
P/S Multiple $31.85 $42.46 $53.08 58
P/B Multiple $93.28 $124.38 $155.47 55
EV/EBIT $72.73 $87.99 $103.25 66
EV/EBITDA $74.59 $90.48 $106.36 67
EV/Revenue $52.42 $63.34 $74.25 54
Asset-Based
NCAV (Graham) $19.64 $29.75 $37.19 54
Growth DCF
Growth DCF $66.21 $76.26 $92.44 80
Rev-Margin DCF $56.92 $68.30 $82.81 74
Economic Profit
Residual Income $30.93 $33.33 $36.98 76
ROIC Compounder $48.35 $51.75 $55.06 72
Growth Earnings
Growth-Adj P/E $41.34 $59.06 $76.78 67

Open the full fair value analysis →

Quality Score breakdown

Overall quality 75/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 49
How much profit the company makes from its sales and capital
Quality Growth 17
Are margins and returns getting better?
Cashflow 88
Do the profits arrive as real cash?
Financial strength 83
Debt, balance sheet and risk of trouble
Investment 98
Does it invest with discipline instead of growing at any price?
Low Volatility 85
How calm the share price moves, does not count
Price momentum 57
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 72
Distance to the 52-week high, does not count
New shares 99
Buys back shares or issues new ones?

Open the full quality analysis →

Insider trades

In the last 6 months, one officer or director bought shares worth $66,750, on Oct 29, 2026.

  • BuyKevin L CornwellChairman, CEO, Director1,000 shares at $66.75$66,750Oct 29, 2026

Plus 2 other filings such as grants, option exercises or tax withholding. They are not market purchases or sales.

Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.

Source: SEC Form 4, as of Nov 6, 2026. All filings at the SEC ↗

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 40/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−5.8%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−9.7%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−1.8%
Start year 2020 (pandemic). Over 10 years: −0.4% a year
Revenue growth 38 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+4.4%
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
−2.0%
Earnings growth per share plus dividend.
Earnings per share, growth per year−2.4%
Dividend (yield on the price)0.4%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.−2.4% vs 1.0%, slowing
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.33% → 30%
Pace: the 5-year rate starts in 2020 (pandemic)

Growth Forecast

Price in line with expectations
The price assumes about as much growth as the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+0.8%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (USA: IMF forecast 2.4% a year to 2030, 3.1% from 2016 to 2025) that is about −1.6% a year for the price.

Watch UTMD, get fair value alerts →

Compare Utah Medical Products Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Instruments & Supplies · 181 stocks

Beats the industry median on 9/14 measures
Overall it ranks above its industry peers.
Valuation
Quality Score 75 · Top 25%
Fair Value upside +5.6% · Above median
Profitability
Return on equity (12 months) 8.8% · Above median
Return on assets 9.2% · Top 25%
Net margin (12 months) 30.5% · Top 25%
Operating margin (12 months) 34.8% · Top 25%
Growth and dividend
Revenue growth (quarter YoY) −12.1% · Bottom 25%
Dividend yield (12 months) 0.4% · Bottom 25%

Valuation Multiplesvs Medical Instruments & Supplies median · lower = cheaper

P/E (12 months) 21.6× · Cheaper than median
P/B 1.93× · Pricier than median
P/S (12 months) 6.59× · Priciest 25%
Price / free cash flow (fiscal year) 16.1× · Cheaper than median
EV/EBITDA 10.8× · Cheaper than median
PEG 4.25× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)41 · sector 25
FUTURE (revenue growth)0 · sector 40
PAST (return on equity)35 · sector 30
HEALTH (low debt)100 · sector 96
DIVIDEND (yield)9 · sector 32

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Instruments & Supplies stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Solventum Corporation SOLV $90.38 $131.27 +45% vs UTMD
EssilorLuxottica Société anonyme EL €193.80 €196.22 +1% vs UTMD
Intuitive Surgical, Inc ISRG $452.80 $353.90 −22% vs UTMD
Medline Inc MDLN $39.64 $28.59 −28% vs UTMD
Alcon Inc ALC CHF 61.30 CHF 34.06 −44% vs UTMD
Becton, Dickinson and Company BDX $211.88 $97.80 −54% vs UTMD
Straumann Holding STMN CHF 104.50 CHF 45.50 −56% vs UTMD
West Pharmaceutical Services, Inc WST $399.81 $139.22 −65% vs UTMD
Sartorius Stedim Biotech S.A DIM €225.80 €54.82 −76% vs UTMD
Sartorius Aktiengesellschaft SRT €227.00 €42.50 −81% vs UTMD

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Utah Medical Products Inc: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Utah Medical Products Inc Fair Value". https://www.fairvalue-calculator.com/stock/UTMD

Frequently asked questions

Is Utah Medical Products Inc (UTMD) overvalued or undervalued?
As of Nov 6, 2026, our model estimates a fair value of $76.26 versus a price of $72.23, about +6% upside (fairly valued).
What is the fair value of UTMD?
Our model-based fair value for Utah Medical Products Inc is $76.26 (as of Nov 6, 2026), built from audited fundamentals. The current price: $72.23.
What is the quality score of UTMD?
Utah Medical Products Inc has a Quality Score of 75/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Utah Medical Products Inc (UTMD)?
Our model-based price target is the fair value of $76.26 (as of Nov 6, 2026) from 24 valuation models. Cautious scenario $58.65, optimistic scenario $92.44. It is a calculation from audited fundamentals, not an analyst target.
What is the Utah Medical Products Inc stock forecast for 2026?
Our models put fair value at $76.26, about +6% upside versus a price of $72.23 (fairly valued). Cautious scenario $58.65, optimistic scenario $92.44. The calculation is refreshed regularly with new filings.
What is the revenue of Utah Medical Products Inc (UTMD)?
Utah Medical Products Inc reported trailing-twelve-month revenue of about $34.9M (latest available figure, as of Nov 6, 2026).
Does Utah Medical Products Inc pay a dividend?
Utah Medical Products Inc currently shows a dividend yield of 0.43% relative to its recent price (as of Nov 6, 2026).
How much is the dividend of Utah Medical Products Inc (UTMD) and when is the ex-dividend date?
Utah Medical Products Inc pays a dividend of $0.31 per share a year, a dividend yield of 0.4%. The last ex-dividend date was Sep 17, 2026. A dividend has been paid every year since 2004. The payout ratio is 9.3% of earnings. Free cash flow covers the dividend 14.55 times. Our assessment: Well covered. A low payout and the dividend is fully funded by free cash flow, a comfortable, sustainable dividend.
What growth is priced into Utah Medical Products Inc (UTMD)?
For today's price to be fair in a discounted-cash-flow model, Utah Medical Products Inc would have to grow free cash flow by +0.8 % per year for five years (discount rate 11.2 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew -1.8 % per year. As of Nov 6, 2026.
What discount rate (WACC) does the fair value of UTMD use?
Our models discount Utah Medical Products Inc at 11.2 %: a base by market capitalisation (micro), damped by beta 0.39, country premium for USA. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Utah Medical Products Inc that is +0.8 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (11.2 %) and the same formula as our fair value.
How much growth has Utah Medical Products Inc (UTMD) delivered so far?
Over the past 5 years revenue at Utah Medical Products Inc grew -1.8 % a year. The price currently implies free-cash-flow growth of +0.8 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Utah Medical Products Inc (UTMD) growing?
The median revenue growth in the sector is +6.2 % a year. That is the yardstick for the growth priced into Utah Medical Products Inc (+0.8 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Utah Medical Products Inc (UTMD)?
The free-cash-flow yield on the price is 6.23 %: that much free cash flow Utah Medical Products Inc produces per unit of market value. When it exceeds the discount rate of our models (11.2 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Utah Medical Products Inc (UTMD)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Utah Medical Products Inc it is $76.26 per share (as of Nov 6, 2026), against a price of $72.23. It is the blended result of 24 valuation models in 8 families (DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings).
Is Utah Medical Products Inc stock overvalued or undervalued in 2026?
As of Nov 6, 2026, UTMD trades below its calculated fair value: price $72.23, fair value $76.26, a gap of about +6% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of UTMD?
No. The price is what the market pays today ($72.23); the fair value is what the company's own numbers justify ($76.26). For Utah Medical Products Inc the two are $4.03 per share apart. That gap is exactly why we show both numbers side by side.
How much is Utah Medical Products Inc worth?
The market values Utah Medical Products Inc at about $230M (market capitalisation, as of Nov 6, 2026). Per share that is $72.23; our models calculate a fair value of $76.26 per share.
What do the bullish and bearish scenarios say about UTMD?
Our models span a range for Utah Medical Products Inc: cautious scenario $58.65, base $76.26, optimistic $92.44 per share (as of Nov 6, 2026, price $72.23). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of UTMD?
Utah Medical Products Inc trades at a price-to-earnings ratio of 21.6 (as of Nov 6, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of $76.26 is built from several models across several years. Median P/E at fiscal year-end, 10 fiscal years (2016 to 2025), reported earnings: 22.4. Other multiples: PEG 4.3, P/B 1.9, P/S 6.6, EV/EBITDA 10.8.
What is the PEG ratio of UTMD?
The PEG ratio of Utah Medical Products Inc is 4.25 (P/E divided by earnings growth, as of Nov 6, 2026). That is above 1, so the growth is already paid for in the price.
How solid is the balance sheet of Utah Medical Products Inc (UTMD)?
Balance-sheet figures for Utah Medical Products Inc (as of Nov 6, 2026): return on equity 8.8%. They feed the Quality Score of 75/100, which measures business quality independently of the share price.
How far is UTMD from its 52-week high?
Utah Medical Products Inc trades at $72.23, about 6% below its 52-week high of $76.66 and 37% above the low of $52.78 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of $76.26 is for.
Which stocks are comparable to Utah Medical Products Inc?
From the same area (Healthcare) we also value Intuitive Surgical, Inc, EssilorLuxottica Société anonyme, Becton, Dickinson and Company, Medline Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Utah Medical Products Inc stock attractive at the current price?
The data as of Nov 6, 2026: price $72.23, calculated fair value $76.26 (+6%), Quality Score 75/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of UTMD calculated?
We run Utah Medical Products Inc through 24 models from 8 families: DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of $76.26 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Utah Medical Products Inc currently trades 5% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Utah Medical Products Inc (UTMD)?
The closing price on Nov 6, 2026 was $72.23. Our model-based fair value is $76.26, about +6% upside (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Utah Medical Products Inc right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. The price sits in the lower half of our model range, the side with the larger margin of safety. The data supports the verdict: every model runs on fully documented inputs.
Where does the earnings growth of Utah Medical Products Inc (UTMD) come from?
Earnings per share at Utah Medical Products Inc grew +2.9 % a year from 2014 to 2025. Broken into its drivers: revenue per share +1.8 %, EBIT margin −2.3 %, tax rate +1.1 %, residual (interest, one-offs) +2.3 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.

Key figures of Utah Medical Products Inc

How large is the market capitalisation of Utah Medical Products Inc (UTMD)?
The market capitalisation of Utah Medical Products Inc is $230M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Utah Medical Products Inc (UTMD)?
The price-to-sales ratio of Utah Medical Products Inc is 6.59 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Utah Medical Products Inc (UTMD)?
Earnings per share at Utah Medical Products Inc are $3.34 (price ÷ EPS = P/E 21.6). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Utah Medical Products Inc (UTMD)?
The dividend yield of Utah Medical Products Inc is 0.4% (payout 9.3%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Utah Medical Products Inc (UTMD)?
The net margin of Utah Medical Products Inc is 30.5% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Utah Medical Products Inc (UTMD)?
The return on equity (ROE) of Utah Medical Products Inc is 8.8% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Utah Medical Products Inc (UTMD)?
On an EBIT basis the return on assets of Utah Medical Products Inc is 13.0% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Utah Medical Products Inc (UTMD)?
The operating margin of Utah Medical Products Inc is 34.8% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Utah Medical Products Inc (UTMD)?
Revenue at Utah Medical Products Inc is growing −12.1% versus a year earlier (3y avg −9.7%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Utah Medical Products Inc (UTMD)?
Earnings per share at Utah Medical Products Inc are growing +6.8% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net cash does Utah Medical Products Inc (UTMD) hold?
Utah Medical Products Inc holds more cash than debt, $85.5M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Utah Medical Products Inc in the live analysis

One click puts Utah Medical Products Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.